Pimasertib

DB14904InvestigationalSmall molecule

Pimasertib is under investigation in clinical trial NCT01378377 (Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus).

Mechanism: Pharmacologically active on Dual specificity mitogen-activated protein kinase kinase 1 and Dual specificity mitogen-activated protein kinase kinase 2
Curator reviewed
Formula / weight: C₁₅H₁₅FIN₃O₃ · 431.206 g/mol (avg)
Also known as: N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)pyridine-4-carboxamide
Code names: AS703026 · EMD 1036239

Resolves to

Compound

Structure

InChIKeyVIUAUNHCRHHYNE-JTQLQIEISA-NSMILESOC[C@@H](O)CNC(=O)C1=C(NC2=C(F)C=C(I)C=C2)C=NC=C1

Targets

What you can answer from here — as of September 12, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

15Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Pimasertib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.